Eli Lilly and Company have announced that Sue Mahony, Ph.D., senior vice president of Lilly and president of Lilly Oncology, will retire at the end of August after 18 years of service with the company. Mahony is also a member of Lilly’s executive committee.
Mahony led Lilly Oncology through the integration of ImClone, successfully launched several key brands—including Verzenio™—and most recently led the refocusing of the company’s oncology R&D strategy. Prior to this, as senior vice president of human resources and diversity, Mahony played a key role in restructuring the company into business units.
“What I’ve appreciated over the years is the opportunity to participate in something greater than myself. What a privilege it’s been to wake up each morning with that as my life’s work.”
Mahony joined Lilly in 2000 after more than a decade in sales and marketing roles in Europe for Schering-Plough, Amgen and Bristol-Myers Squibb. At Lilly, Mahony has held senior leadership positions in product development, Six Sigma, marketing and general management roles.
David A. Ricks, Lilly’s chairman and chief executive officer said, “On behalf of our executive team and the company, I want to thank Sue for her leadership over the past 18 years. Her passion for patients and strong sense of purpose are inspiring to all of us.”
Sue Mahony commented, “What I’ve appreciated over the years is the opportunity to participate in something greater than myself. We make medicines that help patients with cancer live longer. What a privilege it’s been to wake up each morning with that as my life’s work.”
Lilly is considering internal and external candidates to succeed Mahony.